Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice

Silvia Bolland, Young Sun Yim, Katalin Tus, Edward K. Wakeland, Jeffrey V. Ravetch

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

FcγRIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice deficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis displayed by this gene we have constructed hybrids between FcγRIIB-/- and the systemic lupus erythematosus (SLE) modifiers yaa and lpr and the susceptibility locus Sle1. Sle1 and B6.RIIB-/- are both physically and functionally coupled; compound heterozygotes of Slel and B6.RIIB-/- develop significant disease, while single heterozygotes display no evidence of autoimmunity or disease, indicating that these genes he on the same genetic pathway resulting in the loss of tolerance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for the severity of autoimmune disease in this model, as demonstrated by analysis of yaa and lpr hybrids. Thus, B6.RIIB-/-/lpr mice are protected from disease progression, despite equivalent titers of ANA. In contrast, B6.RIIB-/-/yaa mice have significantly enhanced disease despite reduced ANA titers. Yaa modifies the specificity and thus the pathogenicity of the B6. RIIB-/- ANA, by converting them to antinucleolar antibodies. In addition to these known modifier pathways, we have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required for the ANA phenotype, further indicating the epistatic properties of this SLE model.

Original languageEnglish (US)
Pages (from-to)1167-1174
Number of pages8
JournalJournal of Experimental Medicine
Volume195
Issue number9
DOIs
StatePublished - May 6 2002

Fingerprint

Antinuclear Antibodies
Systemic Lupus Erythematosus
Heterozygote
Genes
Nuclear Antigens
Glomerulonephritis
Autoimmunity
Autoimmune Diseases
Virulence
Disease Progression
Genome
Phenotype
Antibodies

Keywords

  • Autoantibodies
  • Glomerulonephritis
  • lpr
  • Sle1
  • Yaa

ASJC Scopus subject areas

  • Immunology

Cite this

Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice. / Bolland, Silvia; Yim, Young Sun; Tus, Katalin; Wakeland, Edward K.; Ravetch, Jeffrey V.

In: Journal of Experimental Medicine, Vol. 195, No. 9, 06.05.2002, p. 1167-1174.

Research output: Contribution to journalArticle

Bolland, Silvia ; Yim, Young Sun ; Tus, Katalin ; Wakeland, Edward K. ; Ravetch, Jeffrey V. / Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice. In: Journal of Experimental Medicine. 2002 ; Vol. 195, No. 9. pp. 1167-1174.
@article{96c3c653cf3f497abafb0412d4559304,
title = "Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice",
abstract = "FcγRIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice deficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis displayed by this gene we have constructed hybrids between FcγRIIB-/- and the systemic lupus erythematosus (SLE) modifiers yaa and lpr and the susceptibility locus Sle1. Sle1 and B6.RIIB-/- are both physically and functionally coupled; compound heterozygotes of Slel and B6.RIIB-/- develop significant disease, while single heterozygotes display no evidence of autoimmunity or disease, indicating that these genes he on the same genetic pathway resulting in the loss of tolerance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for the severity of autoimmune disease in this model, as demonstrated by analysis of yaa and lpr hybrids. Thus, B6.RIIB-/-/lpr mice are protected from disease progression, despite equivalent titers of ANA. In contrast, B6.RIIB-/-/yaa mice have significantly enhanced disease despite reduced ANA titers. Yaa modifies the specificity and thus the pathogenicity of the B6. RIIB-/- ANA, by converting them to antinucleolar antibodies. In addition to these known modifier pathways, we have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required for the ANA phenotype, further indicating the epistatic properties of this SLE model.",
keywords = "Autoantibodies, Glomerulonephritis, lpr, Sle1, Yaa",
author = "Silvia Bolland and Yim, {Young Sun} and Katalin Tus and Wakeland, {Edward K.} and Ravetch, {Jeffrey V.}",
year = "2002",
month = "5",
day = "6",
doi = "10.1084/jem.20020165",
language = "English (US)",
volume = "195",
pages = "1167--1174",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "9",

}

TY - JOUR

T1 - Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice

AU - Bolland, Silvia

AU - Yim, Young Sun

AU - Tus, Katalin

AU - Wakeland, Edward K.

AU - Ravetch, Jeffrey V.

PY - 2002/5/6

Y1 - 2002/5/6

N2 - FcγRIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice deficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis displayed by this gene we have constructed hybrids between FcγRIIB-/- and the systemic lupus erythematosus (SLE) modifiers yaa and lpr and the susceptibility locus Sle1. Sle1 and B6.RIIB-/- are both physically and functionally coupled; compound heterozygotes of Slel and B6.RIIB-/- develop significant disease, while single heterozygotes display no evidence of autoimmunity or disease, indicating that these genes he on the same genetic pathway resulting in the loss of tolerance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for the severity of autoimmune disease in this model, as demonstrated by analysis of yaa and lpr hybrids. Thus, B6.RIIB-/-/lpr mice are protected from disease progression, despite equivalent titers of ANA. In contrast, B6.RIIB-/-/yaa mice have significantly enhanced disease despite reduced ANA titers. Yaa modifies the specificity and thus the pathogenicity of the B6. RIIB-/- ANA, by converting them to antinucleolar antibodies. In addition to these known modifier pathways, we have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required for the ANA phenotype, further indicating the epistatic properties of this SLE model.

AB - FcγRIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice deficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis displayed by this gene we have constructed hybrids between FcγRIIB-/- and the systemic lupus erythematosus (SLE) modifiers yaa and lpr and the susceptibility locus Sle1. Sle1 and B6.RIIB-/- are both physically and functionally coupled; compound heterozygotes of Slel and B6.RIIB-/- develop significant disease, while single heterozygotes display no evidence of autoimmunity or disease, indicating that these genes he on the same genetic pathway resulting in the loss of tolerance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for the severity of autoimmune disease in this model, as demonstrated by analysis of yaa and lpr hybrids. Thus, B6.RIIB-/-/lpr mice are protected from disease progression, despite equivalent titers of ANA. In contrast, B6.RIIB-/-/yaa mice have significantly enhanced disease despite reduced ANA titers. Yaa modifies the specificity and thus the pathogenicity of the B6. RIIB-/- ANA, by converting them to antinucleolar antibodies. In addition to these known modifier pathways, we have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required for the ANA phenotype, further indicating the epistatic properties of this SLE model.

KW - Autoantibodies

KW - Glomerulonephritis

KW - lpr

KW - Sle1

KW - Yaa

UR - http://www.scopus.com/inward/record.url?scp=0037029604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037029604&partnerID=8YFLogxK

U2 - 10.1084/jem.20020165

DO - 10.1084/jem.20020165

M3 - Article

C2 - 11994421

AN - SCOPUS:0037029604

VL - 195

SP - 1167

EP - 1174

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 9

ER -